9592.SR(9592.SR)
9592.SR
Almujtama Alraida Medical Co. operates primarily in the pharmaceutical sector within Saudi Arabia, focusing on the distribution and marketing of medical products. Its competitive position is bolstered by a strong local network and partnerships with international pharmaceutical companies, allowing it to leverage a diverse product portfolio in a growing healthcare market.
Almujtama Alraida generates revenue through the distribution of pharmaceuticals and medical devices, leveraging its established relationships with healthcare providers and hospitals in Saudi Arabia. The company benefits from pricing power due to its exclusive distribution agreements with key international brands, which enhances its competitive advantage in the local market.
Changes in healthcare regulations in Saudi Arabia
Partnerships with new pharmaceutical brands
Market demand for medical devices and pharmaceuticals
Fluctuations in raw material costs affecting margins
Regulatory changes impacting pharmaceutical pricing and distribution
Technological disruption in medical product delivery
Increased competition from local and international pharmaceutical companies
Potential loss of exclusive distribution agreements
High debt levels relative to equity could strain financial flexibility
Low free cash flow may limit investment in growth opportunities
moderate - The company's performance is somewhat linked to GDP growth and consumer spending on healthcare, but the essential nature of pharmaceuticals provides some insulation against economic downturns.
Interest rates affect the company's financing costs, particularly given its debt-to-equity ratio of 1.28, which could impact its ability to invest in growth or manage cash flow effectively.
minimal - The company does not heavily rely on credit for operations, but higher interest rates could increase financing costs.
value - Given its low price-to-sales ratio of 0.5x, investors may see potential for undervaluation.
moderate - The stock has experienced significant price fluctuations, evidenced by a 26.7% decline over the past year.